Network Point-of-Care Glucose Testing Market Size | US$ 3.3 Billion by 2030

The global Network Point-of-Care Glucose Testing market size is expected to be surpass around US$ 5.6 billion by 2030 from valued at US$ 3.3 billion in 2020 and is anticipated to grow at a CAGR of 5.10% from 2021 to 2030.

Report Highlights

• The Accu-Chek Inform II held the largest revenue share of over 45.0% in 2020.
• i-STAT is expected to expand at a CAGR of 4.2% over the forecast period.
• North America dominated the market in 2020 with a revenue share of over 35.0%.
• Europe is expected to expand at a lucrative growth rate during the forecast period.

Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/38458

Growth Factors

Increasing demand for safe and accurate remote patient monitoring options and the need for data-based treatment regimens are major factors driving the market. The integration of advanced technologies including Bluetooth Low Energy (BLE) and Infrared is expected to fuel the market growth in the upcoming years.

Expanding patient base in Asia Pacific and the Middle East and the high demand for advanced diabetes management systems are creating significant growth opportunities in these regions. These regions also include some of the highly preferred destinations for medical tourism. Increasing demand for world-class healthcare services and rising adoption of advanced technology are some of the factors boosting the market growth in these regions.

Product Insights

The Accu-Chek Inform II held the largest revenue share of over 45.0% in 2020. The Accu-Chek Inform II glucose meter is designed for in-vitro diagnostic applications aiding in the determination of blood glucose levels. This glucose meter monitors blood glucose levels in capillary, venous, neonatal and arterial, and whole blood samples. Healthcare professionals adopt Accu-Chek Inform II as it serves as a bedside system that aids in the measurement of glucose and automates the management of data generated by blood glucose tests.

i-STAT is expected to expand at a CAGR of 4.2% over the forecast period. i-STAT portable clinical analyzer developed by Abbott is one of the POC analyzers used at patients’ bedside for critical care tests for electrolytes, coagulation, blood gases, and metabolites. The device is equipped with a number of testing cartridges for monitoring different sets of analytes, which eliminates the need for several analyzers for different analytes.

Regional Insights

North America dominated the market in 2020 with a revenue share of over 35.0%. The presence of key market players such as Abbott, Nova Biomedical, and Prodigy Diabetes Care, LLC is one of the major factors contributing to the regional market growth. This has increased the availability of glucose testing products, thereby contributing to revenue generation. In addition, favorable reimbursement policies aid in the rapid adoption of advanced products.

Europe is expected to expand at a lucrative growth rate during the forecast period. Faster CE approvals and universal healthcare systems are expected to boost the adoption of point-of-care glucose testing devices. The growth can be attributed to various factors such as the rising burden of diabetes, the increasing demand for rapid diagnostic tools for diabetes management, and the presence of local players, which have diverse product portfolios for POC diagnostics. For instance, HemoCue AB is a POC diagnostics company, situated in Sweden, offering POC testing solutions for better management of diabetes.

Key Players

• F. Hoffmann-La Roche Ltd.
• Abbott
• Nova Biomedical
• Bayer AG/Ascensia diabetes care holdings AG
• Danaher

Market Segmentation

• Product
  • i-STAT
  • Accu-Chek Inform II
  • StatStrip
  • HemoCue
  • CareSens Expert Plus
  • BAROzen H Expert Plus

Click Here to View Full Report Table of Contents

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38458

You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333